<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812266</url>
  </required_header>
  <id_info>
    <org_study_id>DOLG7</org_study_id>
    <secondary_id>DOLG7</secondary_id>
    <nct_id>NCT00812266</nct_id>
  </id_info>
  <brief_title>Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)</brief_title>
  <official_title>Randomized Phase III Trial of Topotecan and Cisplatin Versus Etoposide and Carboplatin in the Treatment of Patients With Previously Untreated Small Cell Lung Cancer and Extensive Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Oncological Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Oncological Lung Cancer Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a
      combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell
      type.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fase III, multicenter randomised trial comparing up to six cycles of carboplatin and
      etoposide with up to six cycles of topotecan and cisplatin in patients with extensive stage
      small cell lung cancer and PS 0-3
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 years survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">281</enrollment>
  <condition>Extensive Disease</condition>
  <condition>First-Line</condition>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topotecan + cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etoposide + carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan + cisplatin</intervention_name>
    <description>topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide + carboplatin</intervention_name>
    <description>Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed SCLC

          -  Extensive stage

          -  No prior chemotherapy

          -  WHO PS 0-3

          -  Adequate organ function (liver, kidney)

          -  Adequate hematology (bone marrow)

          -  Informed consent

        Exclusion Criteria:

          -  PS 4

          -  Inadequate organ function

          -  Uncontrolled infection

          -  Concomitant major medical contraindications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seppo W Langer, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Oncology, Rigshospitalet, Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. Oncology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <last_update_submitted>January 23, 2016</last_update_submitted>
  <last_update_submitted_qc>January 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Oncological Lung Cancer Group</investigator_affiliation>
    <investigator_full_name>Seppo W. Langer</investigator_full_name>
    <investigator_title>MD pHD</investigator_title>
  </responsible_party>
  <keyword>SCLC</keyword>
  <keyword>Extensive disease</keyword>
  <keyword>topotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

